

List of insider information under Art. 7 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 regarding market abuse (Regulation on market abuse) for the first quarter of 2019

Dated 11 January 2019

NOTIFICATION

Sopharma AD notifies that for December 2018 the Company recorded an increase of sales revenues of 26% compared to the same month of 2017, including 75% increase of domestic sales and a decrease of 1% of export sales.

In 2018 revenue from sales of goods decreased by 3% compared to the same period in 2017, incl. 3% increase in sales for the domestic market and 7% decrease in export sales.

„It's been a year of review - on our 85th anniversary, we looked back to enjoy our successes, to thank the people with whom we've achieved them and celebrate with everyone we want to share our future with. Thank you for sharing! We are proud to have been among the pioneers with two major initiatives - we have distributed shares to all our employees according to their length of service and contribution to the company's successes and distributed the first interim dividend. We have received support from our shareholders for both initiatives, which has always been an important indication for us confirming that we are doing the right thing.“, commented Mr. Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of Sopharma AD.

Dated 30 January 2019

NOTIFICATION

Sopharma AD received a notification for disclosure of a shareholding under Art. 145 of the CUPF Allianz Bulgaria for acquiring shares from the capital of Sopharma AD, as a result of which the shareholding of CUPF Allianz Bulgaria in the capital of Sopharma AD exceeds the limit of 5% and reaches 5.09%.

The date of the registration of the transaction with the Central Depository is 23 January 2019.

Dated 5 February 2019

NOTIFICATION

Sopharma AD notifies that for January 2019 the Company recorded an increase of sales revenues of 1% compared to the same month of 2018, including 15% decrease of domestic sales and an increase of 13% of export sales.

Dated 6 March 2019

NOTIFICATION

Sopharma AD notifies that for February 2019 the Company recorded a decrease of sales revenues of 14% compared to the same month of 2018, including 38% decrease of domestic sales and an increase of 1% of export sales.

During the first two months of 2019 the revenues from sales of production increased by 1% compared to the same period of 2018, including 15% decrease in domestic sales and 13% increase of export sales.